跳至主要内容
临床试验/NCT01388712
NCT01388712Unknown4 期

The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial

Children's Memorial Health Institute, Poland2 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
128
试验地点
2
主要终点
Number of bowel movement per week, without fecal incontinence

研究概览

简要总结

The most common cause of children chronic constipation is functional disorders. Functional constipation is diagnosed after excluding organic causes of constipation (anatomical, neurological, endocrinological) and identification of two symptoms defined by the Rome III criteria. There could be low number of bowel movements (below three times a week), defecation pain, fecal incontinence (once a week), stool consistency or occurrence of large diameter stools. The treatment is change of diet, defecation training and application of laxatives.

The probiotics are defined as living microorganisms, which provided in a proper doses should result in beneficial effect on a host health. The assessment of its characteristic is related to strain of bacteria affiliation.

Taking into the consideration that patients with constipation may experience microflora intestine disorders, using the probiotics can have the positive impact on process of treating this disease. The additional reason for using the probiotics during the constipation treatment is an influence of probiotics on movement of the alimentary canal.

In spite of proved effectiveness of some probiotics' strains further research are required, because clinical significance is ambiguous and the effect is confirmed among patients with short medical history. That's way the further analysis of probiotic Lactobacillus reuteri DSM 17938, which was successful treatment method of chronic constipation amongst children (infants) should be performed.

The primary aim of the study is the assessment of Lactobacillus reuteri DSM 17938 efficacy, provided with macrogol (Forlax), as treatment of constipation in 3-7 years old children. The baseline of estimation is the frequency comparison of bowel movement in children belonging into two groups: Lactobacillus reuteri treatment and placebo.

The secondary aim of the study is the assessment of frequency the additional symptoms connected with defecation disorders: such as: number of pain episodes during defecation, the intensity of pain, number of hard stools, number of fecal incontinence per week, number of macrogol (Forlax) pockets used.

The investigators believe that constipation treatment (laxatives- macrogol) with Lactobacillus reuteri has better efficacy that the same treatment without Lactobacillus reuteri in 3-7 years old children with medical history of chronic constipation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
3 Years 至 7 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children 3-7 years old
  • Occurrence less than three bowel movement per week
  • Medical history from at least two months]
  • Ineffective laxative treatment at least two months
  • The parents approval for child participation in the study and for the treatment

排除标准

  • Well-known, organic cause of constipation (i.e. hypothyroidism, Hirschprung disease, cystis fibrosis)
  • Anatomic defects of the alimentary canal
  • The surgery of the alimentary canal in the past
  • Treatment of antibiotics/probiotics during last two weeks before start of the study

结局指标

主要结局

Number of bowel movement per week, without fecal incontinence

时间窗: 12 weeks

次要结局

  • The number of bowel movements per week(12 weeks)
  • The number of pain episodes during defecation per week,(12 weeks)
  • The number of hard stools(12 weeks)
  • The number of fecal incontinence per week(12 weeks)
  • The number of patients who have to change amount of drug(12 weeks)
  • The number of patients who have to change use of enema.(12 weeks)

研究者

发起方
Children's Memorial Health Institute, Poland
申办方类型
Other
责任方
Principal Investigator
主要研究者

JAROSLAW KIERKUS

Ph.D.

Children's Memorial Health Institute, Poland

研究点 (2)

Loading locations...

相似试验